* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS ROE % Adjusted to Book Value Chart
Oncosem Onkolojik Sistemlernayi ve Ticaret AS Annual Data
IST:ONCSM vs ABT, SYK, MDT: ROE % Adjusted to Book Value Comparison
For the Medical Devices subindustry, Oncosem Onkolojik Sistemlernayi ve Ticaret AS's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Oncosem Onkolojik Sistemlernayi ve Ticaret AS's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Oncosem Onkolojik Sistemlernayi ve Ticaret AS's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 0.41% mean?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) has a ROE % Adjusted to Book Value of 0.41% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Oncosem Onkolojik Sistemlernayi ve Ticaret AS and its competitors.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS's ROE % Adjusted to Book Value too high?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current ROE % Adjusted to Book Value is 0.41%. Overall, Oncosem Onkolojik Sistemlernayi ve Ticaret AS has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Oncosem Onkolojik Sistemlernayi ve Ticaret AS's ROE % Adjusted to Book Value compare to ABT and SYK?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's ROE % Adjusted to Book Value of 0.41% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Oncosem Onkolojik Sistemlernayi ve Ticaret AS and its competitors. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current ROE % Adjusted to Book Value is 0.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) is currently considered Fairly Valued. The stock's GF Value™ is ₺252.15, compared to a current price of ₺252.00 — trading 0.1% below its estimated fair value. The current ROE % Adjusted to Book Value is 0.41%. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM), the current ROE % Adjusted to Book Value is 0.41% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) Overvalued in 2026?
Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock appears to be undervalued.
The current stock price of ₺252.00 is trading 0.1% below its estimated GF Value™ of ₺252.15.
GuruFocus considers Oncosem Onkolojik Sistemlernayi ve Ticaret AS to be Fairly Valued.
Key valuation signals for IST:ONCSM:
ROE % Adjusted to Book Value: 0.41%
GF Value™: ₺252.15 vs. price of ₺252.00 (0.1% below fair value)
No single metric tells the full story. See the IST:ONCSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:ONCSM has been successfully added to your 
